Menu ×

Healthcare & Pharmaceutical

Erectile Dysfunction Drugs Market Segmentation By Therapeutics (Existing drugs and Pipeline drugs); By Mode of Administration (Injections, Oral Medications and Topical Medications); By Distribution Channel (Online Pharmacies, Retail Pharmacies and Hospital Pharmacies) - Global Demand Analysis & Opportunity Outlook 2027

Product Overview

Erectile dysfunction is the incapability to maintain erection during sexual intercourse. It is also termed as impotence primarily caused by physical weakness .The three most common erectile dysfunction drugs available in the market are Viagra, Cialis, ED oral drugs and Levitra. The increasing number of chronic diseases such as hypertension, diabetes and coronary heart disease is expected to upsurge the number of erectile dysfunction patients and in turn increases the demand for the erectile dysfunction drugs. Increasing health awareness about the erectile dysfunction drugs among the patients is expected to fuel the market growth of erectile dysfunction drugs in the coming years.

Market Size and Forecast

The global erectile dysfunction drugs market is anticipated to expand at a CAGR around 5.0% during 2017-2027. The global erectile dysfunction drugs market is anticipated to value at significant market size during the forecast period. The rising awareness regarding the disease and growing geriatric population is the main reason for the expansion of the erectile dysfunction drugs market.

The global erectile dysfunction drugs market can be segmented on the basis of therapeutics, product type, and distribution channel. On the basis of therapeutics, global erectile dysfunction drugs market is further segmented into existing drugs and pipeline drugs. Existing drugs segment is anticipated to grow at the healthy rate over the forecast period .This is attributed to the fact that existing drugs includes the major drug brands such as Viagra,Cialis, Zydena, Mvix. Based on the mode of administration global erectile dysfunction drugs market is segmented into injections, oral Medications and topical medications

By region, global erectile dysfunction drugs market is segmented into North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. North America is anticipated to be the leading region in the global market of the erectile dysfunction market. The major factor that contributes to the high demand for the erectile dysfunction in the North America is presence of healthcare infrastructure, rising demand for drugs related to dysfunction and increasing R&D related to novel drugs molecules. However, Asia-Pacific region is expected to witness robust growth on the account of rising number of geriatric population, developing drug industry and growing occurrences of erectile dysfunction. The government is also taking various initiatives to boost market of erectile dysfunction.

Market Segmentation

Our in-depth analysis segmented the global erectile dysfunction drugs market in the following segments:

By Therapeutics:

  • Existing drugs 
    • Tadalafil (Cialis)
    • Sildenafil Citrate (Viagra)
    • Udenafil (Zydena)
    • Vardenafil (Levitra/Staxyn)
    • Stendra/Spedra (Avanafil)
    • Lodenafil Carbonate (Helleva)
    • Mirodenafil (Mvix)
  • Pipeline drugs 
    • Apomorphine (Uprima)
    • Topiglan
    • Melanocortin Activators
    • Alprostadil (Vitaros)
    • Gene Therapy

By Mode of Administration

  • Injections
  • Oral Medications
  • Topical Medications

By Distribution Channel

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

By Region

The global erectile dysfunction drugs market is further classified on the basis of region as follows:

  • North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis.

Erectile Dysfunction Drugs Market size

Growth Drivers and Challenges

Various factors that are expected to drive the market growth of erectile dysfunction drugs are the increasing prevalence of the chronic diseases, rising geriatric population and changing lifestyle. Additionally, other factors that are expected to propel the erectile dysfunction drugs market are the increasing geriatric product launches by various companies and enhanced clinical development.

Some of the challenges for the erectile dysfunction drugs market are side effects related to drugs, availability of duplicate drugs, social customs that prohibits many patients to get cured by the drugs.

Key Players

  • Pfizer, Inc.
  • Dong-A ST Co., Ltd
  • Eli Lilly and Company,
  • Bayer AG,
  • VIVUS, INC.,
  • Teva Pharmaceutical Industries Ltd.
  • SK chemicals,
  • Meda Pharmaceuticals Inc.,
  • Apricus Biosciences, Inc.,
  • Futura Medical plc.

 

Factors Covered for Market Penetration
Factors to be Considered for maximum ROI
Connect with our Analyst

Privacy Policy | Terms & Conditions

Copyright © 2019 Research Nester. All Rights Reserved